Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IRON
stocks logo

IRON

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.702
+73.64%
--
--
-1.753
+71.9%
--
--
-1.555
-1.58%
Estimates Revision
The market is revising Upward the revenue expectations for Disc Medicine, Inc. (IRON) for FY2026, with the revenue forecasts being adjusted by 13.22% over the past three months. During the same period, the stock price has changed by 54.36%.
Revenue Estimates for FY2026
Revise Upward
up Image
+13.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.27%
In Past 3 Month
Stock Price
Go Up
up Image
+54.36%
In Past 3 Month
Wall Street analysts forecast IRON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRON is 114.91 USD with a low forecast of 91.00 USD and a high forecast of 153.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast IRON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRON is 114.91 USD with a low forecast of 91.00 USD and a high forecast of 153.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.790
sliders
Low
91.00
Averages
114.91
High
153.00
Current: 93.790
sliders
Low
91.00
Averages
114.91
High
153.00
Truist
Buy
maintain
$86 -> $114
2025-11-10
Reason
Truist
Price Target
$86 -> $114
2025-11-10
maintain
Buy
Reason
Truist raised the firm's price target on Disc Medicine to $114 from $86 and keeps a Buy rating on the shares. The firm is updating its model to incorporate Disc's Q3 financial results, the full U.S. bitopertin opportunity in EPP, and an accelerated launch timeline following receipt of the FDA Commissioner's priority review vouchers, the analyst tells investors in a research note.
Stifel
Stephen Willey
resume
$125
2025-11-03
Reason
Stifel
Stephen Willey
Price Target
$125
2025-11-03
resume
Reason
Stifel analyst Stephen Willey resumed coverage of Disc Medicine with a Buy rating and $125 price target. The firm believes the company's clinical-stage portfolio of assets targeting heme biosynthesis and iron bioavailability will prove clinically and commercially relevant across a broad spectrum of hematological disorders, the analyst tells investors. The firm believes the CNPV-accelerated commercialization of bitopertin in erythropoietic and X-linked protoporphyria and favorable confirmatory Phase 3 APOLLO trial prospects "create a clear path to longer-term profitability," the analyst added.
Wedbush
David Nierengarten
Outperform
upgrade
$90 -> $110
2025-10-17
Reason
Wedbush
David Nierengarten
Price Target
$90 -> $110
2025-10-17
upgrade
Outperform
Reason
Wedbush analyst David Nierengarten raised the firm's price target on Disc Medicine to $110 from $90 and keeps an Outperform rating on the shares. The firm notes the company received a Commissioner's National Priority Voucher, reducing drug application review time for bitopertin to 1-2 months. Wedbush expects FDA to decide on Priority Review for bitopertin in EPP/XLP in late November/early December based on a September 30 NDA submission, which could imply regulatory approval by early February 2026.
Raymond James
Strong Buy
maintain
$89 -> $108
2025-10-17
Reason
Raymond James
Price Target
$89 -> $108
2025-10-17
maintain
Strong Buy
Reason
Raymond James raised the firm's price target on Disc Medicine to $108 from $89 and keeps a Strong Buy rating on the shares. The announcement that bitopertin is among the first cohort of drugs to receive the FDA Commissioner's National Priority Voucher is highly positive, potentially accelerating the bitopertin launch in EPP by more than a quarter, and further increasing the firm's confidence in the prospects for accelerated approval, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL -> Overweight
maintain
$132 -> $153
2025-10-17
Reason
Cantor Fitzgerald
Price Target
$132 -> $153
2025-10-17
maintain
NULL -> Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Disc Medicine to $153 from $132 and keeps an Overweight rating on the shares. Disc Medicine announced it was one of the initial recipients of FDA Commissioner's National Priority Voucher for bitopertin in erythropoietic protoporphyria, the analyst tells investors in a research note. A key advantage is that there is a higher likelihood of approval, the firm says.
Truist
initiated
$86
2025-07-21
Reason
Truist
Price Target
$86
2025-07-21
initiated
Reason
Truist initiated coverage of Disc Medicine with a Buy rating and $86 price target. Disc Medicine is a compelling stock to own due to key value drivers that include lead de-risked asset, bitopertin in rare genetic disorder erythropoietic protoporphyria, potential blockbuster anemia agent, DISC-0974, and DISC-3405 in blood disorder polycythemia vera, the analyst tells investors in a research note. The firm sees significant upside potential by the second half of 2026 for accelerated approval of bito, and positive confirmatory data by early-27, and also thinks risk/reward for 0974 is favorable with large upside potential.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Disc Medicine Inc (IRON.O) is -14.51, compared to its 5-year average forward P/E of -10.97. For a more detailed relative valuation and DCF analysis to assess Disc Medicine Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.97
Current PE
-14.51
Overvalued PE
-7.93
Undervalued PE
-14.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.86
Undervalued EV/EBITDA
-8.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
474.36
Current PS
0.00
Overvalued PS
2083.51
Undervalued PS
-1134.78
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IRON News & Events

Events Timeline

(ET)
2025-11-06
08:34:37
Disc Medicine announces Q3 earnings per share of $1.77, surpassing consensus estimate of $1.47
select
2025-10-21 (ET)
2025-10-21
07:22:55
Disc Medicine Prices $250M Spot Secondary Offering at $84.00
select
2025-10-20 (ET)
2025-10-20
07:06:15
Disc Medicine Launches $220M Underwritten Share Offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
10-31Newsfilter
Disc Medicine to Attend Upcoming Investor Conferences

  • Company Announcement: Disc Medicine, Inc. will participate in three upcoming investor conferences, including the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference, with live webcasts available on their website.

  • Company Focus: Disc Medicine is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious hematologic diseases, targeting key biological pathways related to red blood cell biology, heme biosynthesis, and iron homeostasis.

[object Object]
Preview
4.0
10-23TipRanks
Three Stocks Boasting a Perfect 10 Smart Score and Strong Buy Consensus

  • TipRanks Smart Score: TipRanks provides a Smart Score tool that ranks stocks from 1 to 10 based on their potential to outperform the market, identifying Protagonist Therapeutics (PTGX), Praxis Precision Medicines (PRAX), and Disc Medicine (IRON) as top picks with Strong Buy ratings.

  • Protagonist Therapeutics (PTGX): This biopharmaceutical company has seen a nearly 90% stock gain year-to-date, with all 11 analysts rating it as a Buy and an average price target suggesting an 8% upside.

  • Praxis Precision Medicines (PRAX): Focused on CNS disorders, PRAX has gained 140% this year, with 13 out of 14 analysts rating it as a Buy and a price target indicating a potential 54.5% upside.

  • Disc Medicine (IRON): Specializing in treatments for hematologic diseases, IRON stock has increased by 35% in 2025, holding a Strong Buy rating with an average price target suggesting a 30.09% upside.

[object Object]
Preview
8.5
10-21SeekingAlpha
Disc Medicine increases securities offering to achieve a total of $250 million.

  • Public Offering Announcement: Disc Medicine has priced an upsized public offering of common stock and pre-funded warrants, aiming to raise approximately $225 million in gross proceeds.

  • Details of the Offering: The company is selling 2,619,049 shares at $84.00 each, with an existing investor also selling 297,619 shares expected to generate around $25 million.

  • Use of Proceeds: The funds will be utilized to support the commercialization of bitopertin for specific protoporphyrias and to advance research and clinical development of its pipeline candidates.

  • Closing Date: The offering is anticipated to close on October 22, 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Disc Medicine Inc (IRON) stock price today?

The current price of IRON is 93.79 USD — it has increased 1.53 % in the last trading day.

arrow icon

What is Disc Medicine Inc (IRON)'s business?

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

arrow icon

What is the price predicton of IRON Stock?

Wall Street analysts forecast IRON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRON is 114.91 USD with a low forecast of 91.00 USD and a high forecast of 153.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Disc Medicine Inc (IRON)'s revenue for the last quarter?

Disc Medicine Inc revenue for the last quarter amounts to -67.70M USD, increased 106.04 % YoY.

arrow icon

What is Disc Medicine Inc (IRON)'s earnings per share (EPS) for the last quarter?

Disc Medicine Inc. EPS for the last quarter amounts to -47825000.00 USD, increased 175.47 % YoY.

arrow icon

What changes have occurred in the market's expectations for Disc Medicine Inc (IRON)'s fundamentals?

The market is revising Upward the revenue expectations for Disc Medicine, Inc. (IRON) for FY2026, with the revenue forecasts being adjusted by 13.22% over the past three months. During the same period, the stock price has changed by 54.36%.
arrow icon

How many employees does Disc Medicine Inc (IRON). have?

Disc Medicine Inc (IRON) has 84 emplpoyees as of December 05 2025.

arrow icon

What is Disc Medicine Inc (IRON) market cap?

Today IRON has the market capitalization of 3.54B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free